Short interest in NeuroPace Inc (NASDAQ:NPCE) increased during the last reporting period, rising from 308.34K to 449.55K. This put 2.59% of the company's publicly available shares short.

— We have everything you need: full data on over 800 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & ...

Company to report first quarter 2025 financial results on May 13, 2025 -- MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on ...

MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in epilepsy treatment trading at $10.67 per share, announced today that it anticipates minimal impact from ...

April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its ...

MOUNTAIN VIEW, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an ...

April 14, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today provided an update on its ...

MOUNTAIN VIEW, Calif. - NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in epilepsy treatment trading at $10.67 per share, announced today that it anticipates minimal impact ...